Last Updated: August 9, 2026

Details for New Drug Application (NDA): 206426

✉ Email this page to a colleague

NDA 206426 describes RAPIVAB, which is a drug marketed by Biocryst and is included in one NDA. There are two patents protecting this drug. Additional details are available on the RAPIVAB profile page.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. Additional details are available on the peramivir profile page.

Summary for 206426

Tradename:	RAPIVAB
Applicant:	Biocryst
Ingredient:	peramivir
Patents:	2

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 206426

Generic Entry Date for 206426^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: ⤷ Start Trial Dosage: SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INTRAVENOUS			Strength	200MG/20ML (10MG/ML)
Approval Date:	Dec 19, 2014	TE:		RLD:	Yes
Patent:	⤷ Start Trial	Patent Expiration:	Feb 12, 2027	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER
Patent:	⤷ Start Trial	Patent Expiration:	Feb 12, 2027	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER
Patent:	⤷ Start Trial	Patent Expiration:	May 7, 2027	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS

Expired US Patents for NDA 206426

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Biocryst	RAPIVAB	peramivir	SOLUTION;INTRAVENOUS	206426-001	Dec 19, 2014	⤷ Start Trial	⤷ Start Trial
Biocryst	RAPIVAB	peramivir	SOLUTION;INTRAVENOUS	206426-001	Dec 19, 2014	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for 206426

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 206426

Profile for product number 001

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 206426